| Open Document File Size: 59,18 KBShare Result on Facebook
City Darmstadt / Milwaukee / / Company BioMarin Pharmaceutical Inc. / BioMarin Huxley Ltd. / ZyStor Therapeutics Inc. / Merck Serono / Merck KGaA / Genzyme Corporation / BioMarin/Genzyme LLC / BMO Capital Markets / Investors Eugenia Shen BioMarin Pharmaceutical Inc. / Media Susan Berg BioMarin Pharmaceutical Inc. / / Country Germany / / Currency USD / / Event FDA Phase / M&A / Conference Call / Business Partnership / / IndustryTerm biotechnology / clinical and pre-clinical product / treatment of lysosomal storage disorders / therapies for lysosomal storage disorders / platform technology / conference call / healthcare reform / treatment of Lambert Eaton Myasthenic Syndrome / substantial manufacturing advantages / clinical protocol / therapies for orphan diseases / privately-held biotechnology company developing enzyme replacement therapies / investigational product / therapy for the treatment of Pompe disease / treatment of the disease / / MedicalCondition lysosomal storage disorders / About Pompe Disease Pompe disease / Lambert Eaton Myasthenic Syndrome / phenylketonuria / Pompe disease / orphan diseases / serious diseases / lysosomal storage disorder / mucopolysaccharidosis VI / disease / mucopolysaccharidosis I / progressive degenerative disease / PKU / deficiency / / MedicalTreatment enzyme replacement therapies / clinical protocol / enzyme replacement therapy / / Organization U.S. Food and Drug Administration / European Commission / FDA / Securities and Exchange Commission / / Person Jean-Jacques Bienaimé / Lambert Eaton Myasthenic / Loren Peterson / / / Position financial advisor / Chief Executive Officer / President and Chief Executive Officer / internal candidate / / Product Aldurazyme / Kuvan / Myozyme / Naglazyme / ZC-701 / Firdapse™ (amifampridine phosphate) / Late Onset Pompe / / ProvinceOrState Wisconsin / California / / Technology alpha / clinical protocol / biotechnology / biopharmaceuticals / GILT technology / platform technology / / URL www.BMRN.com / /
SocialTag |
Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final